Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos to Acquire BioFocus for $36.5M in Stock

NEW YORK, Sept. 21 (GenomeWeb News) - Dutch biotech Galapagos has reached an agreement to acquire UK-based BioFocus for ₤20.2 million ($36.5 million), Galapagos said in a statement today.

 

According to the terms of the offer, Galapagos will buy the entire issued share capital of BioFocus by Oct. 12. BioFocus will then become part of the Galapagos group with a 30 percent stake in the firm.

 

Galapagos CEO Onno van de Stolpe said that the acquisition is expected to enhance the company's position in the drug discovery market.

 

"We are truly impressed by their drug discovery capabilities [and] we believe that these will greatly accelerate our programs in bone and joint diseases," van de Stolpe said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more